Altogether, this study demonstrates that it is plausible to generate a condensed subset of small molecules that is able to distinguish PMS from RRMS patients and that CP can be used to generate valid individualized evaluations of the MS phenotype. The gene discussed is CP; the disease is myeloid sarcoma.